SOPHiA GENETICS SA (SOPH) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $638M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSOPHiA GENETICS SA (SOPH) trades at $7.61 with MoonshotScore 14/100 (Grade F). SOPHiA GENETICS SA operates as a healthcare technology company.
Price as of Sep 11, 2026 · Last analyzed: Sep 7, 2026SOPHiA GENETICS SA operates as a healthcare technology company. They offer the SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
SOPH stock analysis for 2026: Analysts have set a consensus price target of $11.50 for SOPHiA GENETICS SA, suggesting 51.1% upside from the current price of $7.61. The AI MoonshotScore is 14/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
SOPH: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Momentum (9/10, Strong). Weakest side: Financial Safety (2/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SOPHiA GENETICS SA Company Overview
Who Are SOPH's Competitors?
SOPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| PHR Phreesia, Inc. | $10.17 | -1.64% | $629M | 685-pillar |
| CTEV Claritev Corporation | $36.74 | +1.24% | $626M | — |
| ACCD Accolade, Inc. | $7.02 | 0.00% | $576M | — |
| MDRX Veradigm Inc. | $4.55 | -2.15% | $773M | 509-signal |
| HSTM HealthStream, Inc. | $28.69 | +0.07% | $838M | 885-pillar |
| NRC National Research Corporation | $21.32 | +1.89% | $481M | 725-pillar |
| EVH Evolent Health, Inc | $4.17 | +0.48% | $469M | — |
| CARL CARLSMED, INC. | $14.76 | -1.53% | $401M | 315-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are the Key Risks for SOPH?
Financial-distress signal — its Altman Z-Score of -0.88 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 94% of our measures
- ● Price is current
- ● Latest filing 38 days ago
- ● Covered by analysts
Why 14?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.38 Gross profit per dollar of assets (Business Quality)
- +0.25 12-month price trend (Momentum)
- +0.21 Revenue growth (Growth)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.60 Debt to equity (Financial Strength)
Risk penalties applied
- -1.79 Bankruptcy-risk score in the distress zone
- -1.95 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 58 |
| 2026-08-26 | 58 |
| 2026-08-29 | 58 |
| 2026-09-01 | 14 |
| 2026-09-04 | 14 |
| 2026-09-07 | 14 |
| 2026-09-10 | 15 |
What changed?
The grade moved from 58 to 15 (-43).
Over the same 18 days the stock moved -12.0%.
Quarterly Financial Performance: SOPHiA GENETICS SA
Revenue for SOPHiA GENETICS SA came in at $23.3M during Q2 FY2026, a 7.5% improvement versus the preceding quarter. The company recorded a net loss of $22.4M, with diluted EPS of $-0.30. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in its sector. Across the four most recent quarters, SOPH averaged $-0.29 in diluted EPS.
Financial Health
SOPHiA GENETICS SA's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.88 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -40.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.3%, the inverse of the P/E and a quick read on earnings relative to price.
SOPH Valuation & Market Position
With a $638M market cap, SOPHiA GENETICS SA sits in the small-cap segment of the market. Analyst price targets span from $9.00 to $14.00, with a consensus of $11.50. At the current price of $7.61, that implies approximately 51% upside potential. Relative to its peer group, SOPH's quantitative score of 14/100 is below the peer average of 62/100.
Earnings Track Record
SOPHiA GENETICS SA has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 13.6% above estimates on average.
Insider Activity
Over the past six months, SOPHiA GENETICS SA insiders filed 100 SEC Form 4 transactions — 82 sales and 18 purchases. On net that is roughly 262K shares disposed (about $1.9M), a signal worth weighing alongside the fundamentals.
SOPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $23M | -$22M | -$0.30 |
| Q1 FY2026 | $22M | -$19M | -$0.27 |
| Q4 FY2025 | $22M | -$19M | -$0.28 |
| Q3 FY2025 | $19M | -$20M | -$0.30 |
Q2 FY2026 · filed 4 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
SOPH Latest News
-
SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise
Yahoo! Finance: SOPH News · Sep 4, 2026
-
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?
defenseworld.net · Aug 25, 2026
-
SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript
Yahoo! Finance: SOPH News · Aug 11, 2026
-
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
Yahoo! Finance: SOPH News · Aug 8, 2026
SOPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SOPH.
Price Targets
Median: $11.50 (+51.1% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
SOPH MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. SOPH scores 14/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?
SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
Latest SOPHiA GENETICS SA Analysis
Investor Questions: SOPH Stock
What does the AI Score mean for SOPH?
SOPH holds an AI Score of 14/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is SOPH a good stock?
Stock Expert AI does not rate SOPH buy, sell or hold. SOPHiA GENETICS SA carries a MoonshotScore of 14/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for SOPH?
SOPHiA GENETICS SA (SOPH) holds an AI score of 14/100 (low). Analysts target $11.50 (+51%). Not financial advice.
How frequently does SOPH data refresh on this page?
SOPH's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SOPH's recent stock price performance?
SOPHiA GENETICS SA (SOPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SOPH overvalued or undervalued right now?
SOPHiA GENETICS SA (SOPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $11.50 (+51%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SOPH?
Yes, most major brokerages offer fractional shares of SOPHiA GENETICS SA (SOPH) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SOPH's earnings and financial reports?
SOPHiA GENETICS SA (SOPH) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SOPH earnings announcements.
What should investors new to SOPH understand first?
SOPHiA GENETICS SA (SOPH) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 14/100. With a market cap of $638M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.